BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and manufacturing organization (CDMO) business.

Photo: Ms. Nedira Salzman-Frenkel

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/297382_f1227e55d4093b4e_002 ...

"We are pleased to welcome Nedira to our team to lead business development for BioHarvest's CDMO, aligned with our strategy of building long-term partnerships with customers," Dr. Zaki Rakib commented. "Nedira brings over a decade of experience in the life sciences industry, including securing contracts with pharmaceutical companies and other related sectors. She has strong experience leading licensing deals, operational scaling, and building cross-functional teams. Nedira will work closely with me to deliver on our revenue targets, in line with our anticipated growth and the launch of our new facility next year."

Previously, Ms. Salzman-Frenkel was Vice President of Business Development at an Israeli biotech, where she spearheaded BD efforts, resulting in a binding licensing term-sheet with a top global pharmaceutical company for Phase 3 clinical development. Prior to this, Ms. Salzman-Frenkel was CEO of the Salzman Group, a global pharmaceutical and contract research organization (CRO) that was focused on pre-clinical and clinical development of novel, small-molecule therapeutics, while providing services to the pharmaceutical, medical device, and agrochemical industries. During her tenure, Ms. Salzman-Frenkel secured approximately $30 million dollars in CRO contracts across these industries. Prior to this, Ms. Salzman-Frenkel co-founded Beetlebung Pharma Ltd. and Solviva, as well as led business development efforts at Salzman Capital Ventures, Ltd., a firm providing full-service pharmaceutical support, custom laboratory research and development, and drug development consultation.

Schreibe Deinen Kommentar